Effects of Omalizumab on Serum Levels of Substance P, Calcitonin Gene-Related Peptide, Neuropeptide Y, and Interleukin-31 in Patients with Chronic Spontaneous Urticaria
The mechanism of action of omalizumab in urticaria is still not literally known. This study examines the serum values of substance P (SP), calcitonin gene-related peptide (CGRP), neuropeptide Y (NPY), and interleukin-31 (IL-31) in patients using omalizumab. In this study, 30 patients with chronic sp...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2023/8087274 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832547977082699776 |
|---|---|
| author | Cagdas Boyvadoglu Hasan Ulusal Seyithan Taysı Goknur Ozaydin-Yavuz Ibrahim Halil Yavuz Pınar Korkmaz Huseyin Serhat Inaloz |
| author_facet | Cagdas Boyvadoglu Hasan Ulusal Seyithan Taysı Goknur Ozaydin-Yavuz Ibrahim Halil Yavuz Pınar Korkmaz Huseyin Serhat Inaloz |
| author_sort | Cagdas Boyvadoglu |
| collection | DOAJ |
| description | The mechanism of action of omalizumab in urticaria is still not literally known. This study examines the serum values of substance P (SP), calcitonin gene-related peptide (CGRP), neuropeptide Y (NPY), and interleukin-31 (IL-31) in patients using omalizumab. In this study, 30 patients with chronic spontaneous urticaria (CSU) who were going to be treated with omalizumab and 20 healthy volunteers took part. Demographic data, clinical data, and disease activity scores were noted. For serum SP, CGRP, NPY, and IL-31 values, 10 mL of blood were taken from the patients before starting the treatment, 3 months after the treatment, at the end of the 6th month, and from healthy volunteers all at once. The change in values measured at baseline, 3rd month, and 6th month was analyzed by the Friedman Test. The Mann–Whitney U test was used to compare the parameters obtained from the patients and control groups. The significance level was set at p=0.05. SP, CGRP, NPY, and IL-31 values were all statistically significantly lower in the CSU patient group compared to the control group. After treatment, the levels of SP and CGRP in the serum went up, and the levels of serum IL-31 went down. These changes were statistically significant. This study supports the view that omalizumab does not only affect IgE receptors but also affects mast cells through other mechanisms. According to our knowledge, this is the first study to show that omalizumab therapy and serum CGRP levels are related. |
| format | Article |
| id | doaj-art-370c71015fa94ee1899ee34b23f50ebe |
| institution | Kabale University |
| issn | 1466-1861 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-370c71015fa94ee1899ee34b23f50ebe2025-02-03T06:42:46ZengWileyMediators of Inflammation1466-18612023-01-01202310.1155/2023/8087274Effects of Omalizumab on Serum Levels of Substance P, Calcitonin Gene-Related Peptide, Neuropeptide Y, and Interleukin-31 in Patients with Chronic Spontaneous UrticariaCagdas Boyvadoglu0Hasan Ulusal1Seyithan Taysı2Goknur Ozaydin-Yavuz3Ibrahim Halil Yavuz4Pınar Korkmaz5Huseyin Serhat Inaloz6Department of DermatologyDepartment of Medical BiochemistryDepartment of Medical BiochemistryDepartment of DermatologyDepartment of DermatologyDepartment of DermatologyDepartment of DermatologyThe mechanism of action of omalizumab in urticaria is still not literally known. This study examines the serum values of substance P (SP), calcitonin gene-related peptide (CGRP), neuropeptide Y (NPY), and interleukin-31 (IL-31) in patients using omalizumab. In this study, 30 patients with chronic spontaneous urticaria (CSU) who were going to be treated with omalizumab and 20 healthy volunteers took part. Demographic data, clinical data, and disease activity scores were noted. For serum SP, CGRP, NPY, and IL-31 values, 10 mL of blood were taken from the patients before starting the treatment, 3 months after the treatment, at the end of the 6th month, and from healthy volunteers all at once. The change in values measured at baseline, 3rd month, and 6th month was analyzed by the Friedman Test. The Mann–Whitney U test was used to compare the parameters obtained from the patients and control groups. The significance level was set at p=0.05. SP, CGRP, NPY, and IL-31 values were all statistically significantly lower in the CSU patient group compared to the control group. After treatment, the levels of SP and CGRP in the serum went up, and the levels of serum IL-31 went down. These changes were statistically significant. This study supports the view that omalizumab does not only affect IgE receptors but also affects mast cells through other mechanisms. According to our knowledge, this is the first study to show that omalizumab therapy and serum CGRP levels are related.http://dx.doi.org/10.1155/2023/8087274 |
| spellingShingle | Cagdas Boyvadoglu Hasan Ulusal Seyithan Taysı Goknur Ozaydin-Yavuz Ibrahim Halil Yavuz Pınar Korkmaz Huseyin Serhat Inaloz Effects of Omalizumab on Serum Levels of Substance P, Calcitonin Gene-Related Peptide, Neuropeptide Y, and Interleukin-31 in Patients with Chronic Spontaneous Urticaria Mediators of Inflammation |
| title | Effects of Omalizumab on Serum Levels of Substance P, Calcitonin Gene-Related Peptide, Neuropeptide Y, and Interleukin-31 in Patients with Chronic Spontaneous Urticaria |
| title_full | Effects of Omalizumab on Serum Levels of Substance P, Calcitonin Gene-Related Peptide, Neuropeptide Y, and Interleukin-31 in Patients with Chronic Spontaneous Urticaria |
| title_fullStr | Effects of Omalizumab on Serum Levels of Substance P, Calcitonin Gene-Related Peptide, Neuropeptide Y, and Interleukin-31 in Patients with Chronic Spontaneous Urticaria |
| title_full_unstemmed | Effects of Omalizumab on Serum Levels of Substance P, Calcitonin Gene-Related Peptide, Neuropeptide Y, and Interleukin-31 in Patients with Chronic Spontaneous Urticaria |
| title_short | Effects of Omalizumab on Serum Levels of Substance P, Calcitonin Gene-Related Peptide, Neuropeptide Y, and Interleukin-31 in Patients with Chronic Spontaneous Urticaria |
| title_sort | effects of omalizumab on serum levels of substance p calcitonin gene related peptide neuropeptide y and interleukin 31 in patients with chronic spontaneous urticaria |
| url | http://dx.doi.org/10.1155/2023/8087274 |
| work_keys_str_mv | AT cagdasboyvadoglu effectsofomalizumabonserumlevelsofsubstancepcalcitoningenerelatedpeptideneuropeptideyandinterleukin31inpatientswithchronicspontaneousurticaria AT hasanulusal effectsofomalizumabonserumlevelsofsubstancepcalcitoningenerelatedpeptideneuropeptideyandinterleukin31inpatientswithchronicspontaneousurticaria AT seyithantaysı effectsofomalizumabonserumlevelsofsubstancepcalcitoningenerelatedpeptideneuropeptideyandinterleukin31inpatientswithchronicspontaneousurticaria AT goknurozaydinyavuz effectsofomalizumabonserumlevelsofsubstancepcalcitoningenerelatedpeptideneuropeptideyandinterleukin31inpatientswithchronicspontaneousurticaria AT ibrahimhalilyavuz effectsofomalizumabonserumlevelsofsubstancepcalcitoningenerelatedpeptideneuropeptideyandinterleukin31inpatientswithchronicspontaneousurticaria AT pınarkorkmaz effectsofomalizumabonserumlevelsofsubstancepcalcitoningenerelatedpeptideneuropeptideyandinterleukin31inpatientswithchronicspontaneousurticaria AT huseyinserhatinaloz effectsofomalizumabonserumlevelsofsubstancepcalcitoningenerelatedpeptideneuropeptideyandinterleukin31inpatientswithchronicspontaneousurticaria |